The absence of a specific expense line tied to the UK Specials program does not prove the program is negligible. It more likely reflects how costs are consolidated within broader categories such as R&D or absorbed through IFR-related infrastructure that does not appear as a standalone entry. SEC reporting standards only require disaggregated expense disclosure when material. In a program like Specials, where scale is moderate and much of the infrastructure is already in place, direct expenses can be real without being broken out visibly in financial statements.
Revenue from Specials is also not expected to appear immediately under GAAP. For unlicensed biologics, revenue is typically deferred until payment is received and fully collectable. That accounting approach prevents recognition even when patients have been treated. This timing issue is not unique to NWBO but applies across the industry when dealing with early access programs. It means the absence of recorded revenue is not proof of absence of activity, it reflects standard accounting treatment for unapproved therapies.
Multiple UK-based patients have openly sought funds through platforms like GoFundMe, often citing costs between $50,000 and $150,000 to receive DCVax under the Specials framework. That contradicts the suggestion that NWBO could be delivering therapy at no charge. If treatment occurred for hundreds of patients, the associated costs could be reflected in aggregate under IFR operations, partner-managed services, or delayed revenue recognition. The lack of a separate financial line item does not mean the program had no operational or economic presence, it means it was managed within the existing regulatory and accounting frameworks that govern Specials use.
Bullish
AI
Market Data 
Markets 
